Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy
To evaluate the prognostic role of pretreatment 18F-FDG PET/CT metabolic parameters in non-endemic Epstein–Barr Virus (EBV DNA)-related nasopharyngeal cancer (NPC) patients treated with curative intensity-modulated radiation therapy (IMRT) with or without chemotherapy (CHT).
We retrospectively reviewed clinical data of 160 consecutive non-metastatic NPC patients who received IMRT with or without CHT. Forty-nine out of 160 patients that underwent whole body 18F-FDG PET/CT at our institution for disease staging with a minimum follow-up to 12 months were included in this study. We evaluated the relationship between maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume and total lesion glycolysis (TLG) of primary tumor and cervical lymph nodes with disease-free survival (DFS) and overall survival (OS). We also investigated the prognostic role of clinical variables such as age, disease stage, plasma EBV DNA load (copies/ml), gross tumor volume of primary tumor and lymph nodes.
Median follow-up was 55 months. Two- and 5-year OS were 95.8% and 90.5%, respectively, while DFS was 83.4% at both time points. SUVmax of primary tumor ≥ 18.8 g/ml and primary tumor TLG ≥ 203.1 g were significant prognostic factors of worse OS. Furthermore, stages IVB and EBV DNA load ≥ 3493 copies/ml were significantly associated with lower DFS. No correlation was found between PET parameters and plasma EBV DNA load.
Even in a limited series, our data suggested that SUVmax, SUVmean and TLG of primary tumor could predict a poor outcome in NPC patients also in non-endemic area hypothesizing their use for refinement of prognostication.
KeywordsFDG PET/CT Metabolic parameters NPC EBV DNA IMRT
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study have been approved by the institutional committee, and all procedure performed were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
For this type of study, formal consent is not required.
- 3.Pan JJ, Ng WT, Zong JF, Lee SW, Choi HC, Chan LL, Lin SJ, Guo QJ, Sze HC, Chen YB, Xiao YP, Kan WK, O’Sullivan B, Xu W, Le QT, Glastonbury CM, Colevas AD, Weber RS, Lydiatt W, Shah JP, Lee AW (2016) Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122(21):3307–3315PubMedPubMedCentralCrossRefGoogle Scholar
- 4.Huang TL, Hsu HC, Chen HC, Lin HC, Chien CY, Fang FM, Huang CC, Chang HW, Chang WN, Huang CR, Tsai NW, Kung CT, Wang HC, Lin WC, Cheng BC, Su YJ, Chang YT, Chang CR, Tan TY, Lu CH (2013) Long-term effects on carotid intima-media thickness after radiotherapy in patients with nasopharyngeal carcinoma. Radiat Oncol 7(8):261CrossRefGoogle Scholar
- 6.Alfieri S, Iacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, Bossi P (2017) Circulating pre-treatment Epstein–Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. Oncotarget. https://doi.org/10.18632/oncotarget.17822 PubMedPubMedCentralCrossRefGoogle Scholar
- 8.Hsieh TC, Hsieh CY, Yang TY, Chen TT, Lin CY, Lin CC, Hua CH, Chiu CF, Yeh SP, Sher YP (2015) [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value as a predictor of adjuvant chemotherapy benefits in patients with nasopharyngeal carcinoma. Oncologist 20(5):539–545PubMedPubMedCentralCrossRefGoogle Scholar
- 9.Hung TM, Wang HM, Kang CJ, Huang SF, Liao CT, Chan SC, Ng SH, Chen IH, Lin CY, Fan KH, Chang JT (2013) Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncol 49(2):169–174PubMedCrossRefGoogle Scholar
- 10.Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, Chang CJ, Lin SY, Yen TC (2011) Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun 32(11):989–996PubMedCrossRefGoogle Scholar
- 12.Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, Ahn MJ, Park K, Kim BT (2015) Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. Clin Exp Otorhinolaryngol 8(2):142–148PubMedPubMedCentralCrossRefGoogle Scholar
- 14.Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578PubMedCrossRefGoogle Scholar
- 17.Moule RN, Kayani I, Prior T, Lemon C, Goodchild K, Sanghera B, Wong WL, Saunders MI (2011) Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. Clin Oncol (R Coll Radiol) 23(5):364–371CrossRefGoogle Scholar
- 19.Xiao W, Xu A, Han F, Lin X, Lu L, Shen G, Huang S, Fan W, Deng X, Zhao C (2015) Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol 51(4):363–369PubMedCrossRefGoogle Scholar
- 21.Schinagl DA, Vogel WV, Hoffmann AL, van Dalen JA, Oyen WJ, Kaanders JH (2007) Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 69(4):1282–1289PubMedCrossRefGoogle Scholar
- 22.Mazzola R, Alongi P, Ricchetti F, Fiorentino A, Fersino S, Giaj-Levra N, Salgarello M, Alongi F (2017) 18F-fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. Radiol Med 122(12):952–959PubMedCrossRefGoogle Scholar
- 23.Cacicedo J, Fernandez I, Del Hoyo O, Dolado A, Gómez-Suarez J, Hortelano E, Sancho A, Pijoan JI, Alvarez J, Espinosa JM, Gaafar A, Bilbao P (2015) Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? a prospective analysis. Eur J Nucl Med Mol Imaging 42(9):1378–1389PubMedCrossRefGoogle Scholar
- 25.Delouya G, Igidbashian L, Houle A, Bélair M, Boucher L, Cohade C, Beaulieu S, Filion EJ, Coulombe G, Hinse M, Martel C, Després P, Nguyen-Tan PF (2011) 18F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer. Radiother Oncol 101(3):362–368PubMedCrossRefGoogle Scholar